MedTrace Logo

Standardization of Anti-Seizure Medications Withdrawals After Seizure Remission in Young Patients With Epilepsy

NCT05740423 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2023-02-23

No results posted yet for this study

Summary

The proper period of anti-seizure medication (ASM) treamtment is important for decreasing side effect of ASM and recurrence of seizure. We evaluate reliable risk factor analysis for safe withdrawal of ASM in children with epilepsy. Futhermore, we develop the scoring system for prediction of seizure recurrence to set the standard for safe withdrawal of ASM.

Conditions

Sponsors & Collaborators

  • Ministry of Health, Republic of Korea

    collaborator OTHER_GOV

  • Korea Health Industry Development Institute

    collaborator OTHER_GOV

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Min-Sun Yum · Asan Medical Center

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-30
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05740423 on ClinicalTrials.gov